Aevi Genomic Medicine, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2018. For the quarter, the company's operating loss was $8,735,000 compared to $10,935,000 a year ago. Net loss was $8,709,000 compared to $10,917,000 a year ago. Basic and diluted loss per share was $0.15 compared to $0.29 a year ago.